Events

Cambridge Science Festival / Anne Phelan

AI Hype vs. Reality

Data science and AI have the potential to transform the discovery and development of medicines. However, there is a lot of hype surrounding AI. The session will cover: What has been achieved to date? What is realistic to expect from data science and AI in the next 5 to 10 years? How can data science experts manage expectations? How can pharma and tech better collaborate to realise the potential of data science and AI in healthcare?

The interdisciplinary panel will be chaired by Gareth Mitchell, presenter from the BBC's Digital Planet.

Panellists include:

  • Dr Jim Weatherall (Vice President of Data Science & AI, R&D, AstraZeneca),
  • Professor Mihaela van der Schaar (Director, Cambridge Centre for AI in Medicine),
  • Anne Phelan (CSO, BenevolentAI)
  • Dr Junaid Bajwa (Chief Medical Scientist, Microsoft Research).

Register here →


Anne Phelan

Chief Scientific Officer

Anne is Chief Scientific Officer, Head of Preclinical Development and Site Head for the Benevolent Cambridge Laboratories. Anne is responsible for driving the early AI augmented discovery portfolio through Lead Optimisation to delivery of pre-clinical candidate drug molecules. Before joining BenevolentAI, Anne worked for Pharma (Pfizer) and Biotech (Mission Therapeutics), across a wide range of Therapeutic Areas including Fibrosis, Pain, A&R and Neurodegeneration. Anne holds a BSc and PhD in Genetics from the University of Liverpool, UK and has over 25 years experience from early discovery to late stage development

More Posts

You Might Also Like

News
Interim results for the six months ended 30 June 2022
Continued operational progress and strengthened financial position provides capital for key value inflection points and continued investment in leading technology platform.
Sep 27, 2022
News
Analyst / Investor Event
BenevolentAI announces that during its analyst / investor event and interim results presentation being held in London today, new information on the Company’s BEN-2293 Phase Ib study results will be disclosed.
Sep 27, 2022
Blog
Building the data foundations to accelerate drug discovery
Mark Davies, BenevolentAI’s SVP Informatics and Data, discusses innovations that enable BenevolentAI to leverage biomedical data in drug discovery.
Sep 22, 2022
News
Analyst / Investor Event and Interim Results
BenevolentAI is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 – 17:00 BST (09:00 – 12:00 ET) on Tuesday, 27 September 2022.
Sep 16, 2022
Video
Text & Data Mining in Drug Discovery: A Conversation with Springer Nature
Hear Mark Davies, SVP Informatics and Data, speak to Springer Nature about how BenevolentAI is leveraging the scientific literature to expedite drug discovery.
Sep 2, 2022
News
Notice of Interim Results and Analyst / Investor Event
BenevolentAI will announce interim results on the 27th of September and hold an analyst and investor event on the same day. Find out more.
Aug 26, 2022